Long-term follow-up of patients who received CAR-T cell therapy
Follows adults with B-cell blood cancers after receiving CAR-T cell treatment.
Key facts
- Who runs it
- Medical College of Wisconsin
- Where
- Milwaukee, United StatesSee the site
- Trial code
- Registry title
- Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 1 Dec 2017
- Expected to end
- 1 Jan 2035
- Type of study
- Observational
- Treatments tested
- Long-Term Follow-Up of Participants who Received CAR-T cells
- Record updated
- 10 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who joined a CAR-T cell study at Froedtert Hospital and the Medical College of Wisconsin. It follows them over the long term.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Earlier treatment
- People must have taken part in a CAR-T study at Froedtert Hospital and the Medical College of Wisconsin.
Main reasons for not taking part
- The record lists no exclusion criteria.
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin
Who cannot take part
- There are no exclusion criteria for this study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Froedtert Hospital/Medical College of WisconsinMilwaukee, United StatesContact: Cancer Center Clinical Trials OfficeTaking people
About the trial
What the trial wants to find out
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:
Read full original descriptionShow less
Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)
The group in the trial
- Participants who received CAR-T cells.
Participants who received CAR-T cells at Froedtert Hospital \& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).
Treatment: Long-Term Follow-Up of Participants who Received CAR-T cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Plain-language title
- Long-term follow-up of patients who received CAR-T cell therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03375619, who can take part
- Record updated
- 10 November 2025